Stabilized glucagon formulation for bihormonal pump use

Journal of Diabetes Science and Technology

Volumn 4, Issue 6, 2010, Pages 1332-1337

  Steiner, Solomon S ^a   Li, Ming ^a   Hauser, Robert ^a   Pohl, Roderike ^a  

^a Biodel Inc   (United States)

Author keywords

Artificial pancreas; Bihormonal pump; Diabetic miniature swine; Fibril formation; Gelation; Stabilized glucagon

Indexed keywords

ALCOHOL DERIVATIVE; BUFFER; CARBOHYDRATE; GLUCAGON; LYSOPHOSPHATIDYLCHOLINE; REDUCING AGENT;

ARTICLE; CHEMISTRY; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INSULIN INFUSION; PH; SOLUTION AND SOLUBILITY; TEMPERATURE; TIME;

ALCOHOLS; BUFFERS; CARBOHYDRATES; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; GLUCAGON; HYDROGEN-ION CONCENTRATION; INSULIN INFUSION SYSTEMS; LYSOPHOSPHATIDYLCHOLINES; PHARMACEUTICAL SOLUTIONS; REDUCING AGENTS; TEMPERATURE; TIME FACTORS;

EID: 79953003207     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681000400606     Document Type: Conference Paper

References (25)

1. Joshi AB, Rus E, Kirsh LE. The degradation pathways of glucagon in acidic solutions. Int J Pharm. 2000;203(1-2):115-25.
2. Paolisso G, Scheen AJ, Albert A, Lefebvre PJ. Effects of pulsatile delivery of insulin and glucagon in humans. Am J Physiol. 1989;257(5 Pt 1):E686-96
3. Van Bon AC, Kohinor MJ, Hoekstra JB, von Basum G, deVries JH. Patients' perception and future acceptance of an artificial pancreas. J Diabetes Sci Technol. 2010;4(3):596-602.
4. Grosman B, Dassau E, Zisser HC, Jovanovic L, Doyle FJ 3rd. Zone model predictive control: a strategy to minimize hyper-and hypoglycemic events. J Diabetes Sci Technol. 2010;4(4):961-75.
5. Mauseth R, Wang Y, Dassau E, Kircher R Jr, Matheson D, Zisser H, Jovanovic L, Doyle FJ 3rd. Proposed clinical application for tuning fuzzy logic controller of artificial pancreas utilizing a personalization factor. J Diabetes Sci Technol. 2010;4(4):913-22.
6. Pinkos A, Arreaza-Rubin G, Heetderks WJ, Irony I, Joffe HV, Schneider B, Zimliki CL. FDA's proactive role in the development of an artificial pancreas for the treatment of diabetes mellitus. Drug Discov Today Technol. 2007;4(1):25-8.
7. Albisser AM, Jackman WS, Ferguson R, Bahoric A, Goriya Y. A portable precision pumping system for chronic, programmed insulin infusion. Med Prog Technol. 1978;5(4):187-93.
8. Dassau E, Cameron F, Lee H, Bequette BW, Zisser H, Jovanovic L, Chase HP, Wilson DM, Buckingham BA, Doyle FJ 3rd. Real-time hypoglycemia prediction suite using continuous glucose monitoring: a safety net for the artificial pancreas. Diabetes Care. 2010;33(6):1249-54.
9. El-Khatib FH, Russell SJ, Nathan DM, Sutherlin RG, Damiano ER. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med. 2010;2(27):27ra27.
10. Van Bon AC, Hermanides J, Koops R, Hoekstra JB, DeVries JH. Postprandial glycemic excursions with the use of a closed-loop platform in subjects with type 1 diabetes: a pilot study. J Diabetes Sci Technol. 2010;4(4):923-8.
11. Abu-Rmileh A, Garcia-Gabin W, Zambrano D. A robust sliding mode controller with internal model for closed-loop artificial pancreas. Med Biol Eng Comput. 2010. Epub ahead of print.
12. Anhalt H, Bohannon NJ. Insulin patch pumps: their development and future in closed-loop systems. Diabetes Technol Ther. 2010;12 Suppl 1:S51-8.
13. Wilinska ME, Budiman ES, Taub MB, Elleri D, Allen JM, Acerini CL, Dunger DB, Hovorka R. Overnight closed-loop insulin delivery with model predictive control: assessment of hypoglycemia and hyperglycemia risk using simulation studies. J Diabetes Sci Technol. 2009;3(5):1109-20.
14. Lee H, Buckingham BA, Wilson DM, Bequette BW. A closed-loop artificial pancreas using model predictive control and a sliding meal size estimator. J Diabetes Sci Technol. 2009;3(5):1082-90.
15. Valla V. Therapeutics of diabetes mellitus: focus on insulin analogues and insulin pumps. Exp Diabetes Res. 2010;2010:178372.
16. Glucagon for injection. Lilly glucagon package insert.
17. Sasaki K, Dockerill S, Adamiak DA, Tickle IJ, Blundell T. X-ray analysis of glucagon and its relationship to receptor binding. Nature. 1975;257(5529):751-7.
18. Gratzer WB, Beaven GH, Rattle HW, Bradbury EM. A conformational study of glucagon. Eur J Biochem. 1968;3(3):276-83.
19. Beaven GH, Gratzer WB, Davies HG. Formation and structure of gels and fibrils from glucagon. Eur J Biochem. 1969;11(1):37-42.
20. Johnson ML, Formisano S, Edelhoch H. Self-association of glucagon as measured by the optical properties of rhodamine 6G. J Biol Chem. 1978;253(5):1353-6.
21. Johnson RE, Hruby VJ, Rupley JA. Thermodynamics of glucagon aggregation. Biochemistry. 1979;18(7):1176-9.
22. Pedersen JS, Dikov D, FlinkvJL, Hjuler HA, Christiansen G, Otzen DE. The changing face of glucagon fibrillation: structural polymorphism and conformational imprinting. J Mol Biol. 2006;355(3):501-23.
23. Blundell TL. Conformation and molecular biology of polypeptide hormones II. Glucagon. Trens Biochem Sci. 1979;4:80-3.
24. Onoue S, Ohshima K, Debari K, Koh K, Shioda S, Iwasa S, Kashimoto K, Yajima T. Mishandling of the therapeutic peptide glucagon generates cytotoxic amyloidogenic fibrils. Pharm Res. 2004;21(7):1274-83.
25. EL-Khatib FH, Jiang J, Gerrity RG, Damiano ER. Pharmacodynamics and stability of subcutaneously infused glucagon in a type 1 diabetic swine model in vivo. Diabetes Technol Ther. 2007;9(2) 135-44.